AGTR1 and metabolic syndrome: In this study, TRC120038, a novel dual AT1/ETA receptor blocker, on repeated administration, has clearly prevented increase in BP, attenuated progression in the severity of renal dysfunction, and preserved cardiac function in ob-ZSF1, an animal model of metabolic syndrome.